Skip to content
NASDAQ · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · MID CAP

Tactile Systems Technology Inc. TCMD

12 fiscal years on record · USD · FY2025 reported · SEC filings only
$329.5M
▲ 12.5% YoY
$19.1M
▲ 12.5% YoY
$40.4M
▲ 5.7% YoY

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

Tactile Systems Technology, Inc. develops and provides medical devices for the treatment of underserved chronic diseases. For the year ended December 31, 2025, it generated revenue of $329.5 million and net income of $19.1 million. As of December 31, 2025, it employed 166 account managers and 166 specialists supporting its lymphedema products, and a team of 19 specialists supporting its airway clearance products. Its therapeutic focus areas are vascular disease, aimed at treating lymphedema and chronic venous insufficiency; oncology, where lymphedema is a common consequence among cancer survivors; and airway clearance therapy for people with chronic respiratory conditions. Sales and rentals of its lymphedema products generated $278.4 million, or 84% of revenue, in 2025. The AffloVest product line generated $51.1 million, or 16% of revenue, in 2025. Tactile Systems Technology, Inc. was originally incorporated in Minnesota on January 30, 1995.

Written from the business description in TACTILE SYSTEMS TECHNOLOGY INC's annual report to the U.S. Securities and Exchange Commission, filed 17 February 2026. Every sentence was checked against that document before publication.

Growth

USD 329.5M
Revenue, FY2025 · full 12-year series below
Revenue $M Net income $M
FY2025 · Revenue 329.5 · Net income 19.1
150M300M
20142017202020232025
Compound annual growth
+10.1%
+12.0%
+18.0%
+29.9%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +12.0% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

6 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating 8.9% · Net 5.8%
5%10%-2%-4%-6%
201420192025
ROE
FY2025 · ROE 8.8%
5%10%15%-5%-10%
201420192025
Three returns, three denominators.

Each USD of equity produced 9 cents of profit this year.

Cash & shareholders

USD 26.3M
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF 40.4
15M30M
201420192025
Net buybacks $M Dividends $M
FY2025 · Dividends · · Net buybacks 26.3
10M20M
201720242025

USD 26.3M in buybacks — 138% of the year's profit, so the payout drew on cash built up earlier.

Total assetsUSD 273.9M
EquityUSD 218.9M
CashUSD 83.4M
Gross debtUSD 0.00
Net debtUSD -83.4M
Current ratio4.03×

The company holds more cash than debt.

The 12-year record

12 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
TCMD, 12-year financial record
Metric 202520242023202220212020201920182017201620152014
Revenue $B0.30.30.30.20.20.20.20.10.10.10.10.0
Operating income $B0.00.00.0−0.0−0.0−0.00.00.00.00.00.00.0
EBITDA $B0.00.00.0−0.00.0−0.00.00.00.00.00.00.0
Income tax $B0.00.0−0.00.00.0−0.00.0−0.0−0.00.00.00.0
Net income $B0.00.00.0−0.0−0.0−0.00.00.00.00.00.00.0
Free cash flow $B0.00.00.00.00.00.0−0.00.00.00.00.0−0.0
EPS, diluted $0.820.701.23−0.89−0.60−0.030.560.340.310.15−0.150.02
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend————————————
ROE %8.88.318.1−14.3−9.3−0.510.98.28.8———
Shares out B0.020.020.020.020.020.020.020.020.020.020.00◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 58 reconciliationsAUDITED

Reconciled in 12 of the 12 fiscal years we could check. 16 checks were skipped: the balance sheet is not tagged before 2015. Seven checks were skipped: EPS is not tagged before 2014. Seven checks were skipped: revenue is not tagged before 2014.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivitySurgical & Medical Instruments & Apparatus
Listed onNASDAQ
Incorporated inMinnesota
Fiscal year endsDecember 31
Data on record since2014

Share this section

Download image